ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

Fujifilm signs two COVID-19 vaccine pacts

by Michael McCoy
July 31, 2020 | APPEARED IN VOLUME 98, ISSUE 30

 

09830-buscon16-texas.jpg
Credit: Fujifilm
The US government has reserved vaccine production capacity at this Fujifilm facillity in Texas.

The US government will pay $265 million under its Operation Warp Speed program to reserve capacity for manufacturing COVID-19 vaccines at Fujifilm Diosynth Biotechnologies’ facility in College Station, Texas. The government has a similar agreement with Emergent BioSolutions in Maryland. Fujifilm says some of the capacity will be allocated to the vaccine being developed by Novavax. Fujifilm recently signed a deal to manufacture the Novavax vaccine in Morrisville, North Carolina, for clinical trials before transferring production to Texas.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment